| { | |
| "architectures": [ | |
| "BertForSequenceClassification" | |
| ], | |
| "attention_probs_dropout_prob": 0.1, | |
| "classifier_dropout": null, | |
| "dtype": "float32", | |
| "hidden_act": "gelu", | |
| "hidden_dropout_prob": 0.1, | |
| "hidden_size": 768, | |
| "id2label": { | |
| "0": "Benign; No actionable therapy. [COSMIC]", | |
| "1": "Benign; No actionable therapy. [ClinVar]", | |
| "2": "Benign; No actionable therapy. [OncoKB]", | |
| "3": "Founder mutation; Genetic counseling required. [COSMIC]", | |
| "4": "Founder mutation; Genetic counseling required. [ClinVar]", | |
| "5": "Founder mutation; Genetic counseling required. [OncoKB]", | |
| "6": "Likely oncogenic; Chemo to moderate extent. [COSMIC]", | |
| "7": "Likely oncogenic; Chemo to moderate extent. [ClinVar]", | |
| "8": "Likely oncogenic; Chemo to moderate extent. [OncoKB]", | |
| "9": "Likely pathogenic; PARP inhibitors recommended. [COSMIC]", | |
| "10": "Likely pathogenic; PARP inhibitors recommended. [ClinVar]", | |
| "11": "Likely pathogenic; PARP inhibitors recommended. [OncoKB]", | |
| "12": "Oncogenic; TKI therapy (osimertinib). [COSMIC]", | |
| "13": "Oncogenic; TKI therapy (osimertinib). [ClinVar]", | |
| "14": "Oncogenic; TKI therapy (osimertinib). [OncoKB]", | |
| "15": "Pathogenic; Immunotherapy (pembrolizumab) advised. [COSMIC]", | |
| "16": "Pathogenic; Immunotherapy (pembrolizumab) advised. [ClinVar]", | |
| "17": "Pathogenic; Immunotherapy (pembrolizumab) advised. [OncoKB]", | |
| "18": "Pathogenic; Level 1 evidence for olaparib. [COSMIC]", | |
| "19": "Pathogenic; Level 1 evidence for olaparib. [ClinVar]", | |
| "20": "Pathogenic; Level 1 evidence for olaparib. [OncoKB]", | |
| "21": "Resistance mutation; Switch to alternative TKI. [COSMIC]", | |
| "22": "Resistance mutation; Switch to alternative TKI. [ClinVar]", | |
| "23": "Resistance mutation; Switch to alternative TKI. [OncoKB]", | |
| "24": "Truncating variant; Radiation not advised. [COSMIC]", | |
| "25": "Truncating variant; Radiation not advised. [ClinVar]", | |
| "26": "Truncating variant; Radiation not advised. [OncoKB]", | |
| "27": "VUS; Monitor and consider trials. [COSMIC]", | |
| "28": "VUS; Monitor and consider trials. [ClinVar]", | |
| "29": "VUS; Monitor and consider trials. [OncoKB]" | |
| }, | |
| "initializer_range": 0.02, | |
| "intermediate_size": 3072, | |
| "label2id": { | |
| "Benign; No actionable therapy. [COSMIC]": 0, | |
| "Benign; No actionable therapy. [ClinVar]": 1, | |
| "Benign; No actionable therapy. [OncoKB]": 2, | |
| "Founder mutation; Genetic counseling required. [COSMIC]": 3, | |
| "Founder mutation; Genetic counseling required. [ClinVar]": 4, | |
| "Founder mutation; Genetic counseling required. [OncoKB]": 5, | |
| "Likely oncogenic; Chemo to moderate extent. [COSMIC]": 6, | |
| "Likely oncogenic; Chemo to moderate extent. [ClinVar]": 7, | |
| "Likely oncogenic; Chemo to moderate extent. [OncoKB]": 8, | |
| "Likely pathogenic; PARP inhibitors recommended. [COSMIC]": 9, | |
| "Likely pathogenic; PARP inhibitors recommended. [ClinVar]": 10, | |
| "Likely pathogenic; PARP inhibitors recommended. [OncoKB]": 11, | |
| "Oncogenic; TKI therapy (osimertinib). [COSMIC]": 12, | |
| "Oncogenic; TKI therapy (osimertinib). [ClinVar]": 13, | |
| "Oncogenic; TKI therapy (osimertinib). [OncoKB]": 14, | |
| "Pathogenic; Immunotherapy (pembrolizumab) advised. [COSMIC]": 15, | |
| "Pathogenic; Immunotherapy (pembrolizumab) advised. [ClinVar]": 16, | |
| "Pathogenic; Immunotherapy (pembrolizumab) advised. [OncoKB]": 17, | |
| "Pathogenic; Level 1 evidence for olaparib. [COSMIC]": 18, | |
| "Pathogenic; Level 1 evidence for olaparib. [ClinVar]": 19, | |
| "Pathogenic; Level 1 evidence for olaparib. [OncoKB]": 20, | |
| "Resistance mutation; Switch to alternative TKI. [COSMIC]": 21, | |
| "Resistance mutation; Switch to alternative TKI. [ClinVar]": 22, | |
| "Resistance mutation; Switch to alternative TKI. [OncoKB]": 23, | |
| "Truncating variant; Radiation not advised. [COSMIC]": 24, | |
| "Truncating variant; Radiation not advised. [ClinVar]": 25, | |
| "Truncating variant; Radiation not advised. [OncoKB]": 26, | |
| "VUS; Monitor and consider trials. [COSMIC]": 27, | |
| "VUS; Monitor and consider trials. [ClinVar]": 28, | |
| "VUS; Monitor and consider trials. [OncoKB]": 29 | |
| }, | |
| "layer_norm_eps": 1e-12, | |
| "max_position_embeddings": 512, | |
| "model_type": "bert", | |
| "num_attention_heads": 12, | |
| "num_hidden_layers": 12, | |
| "pad_token_id": 0, | |
| "position_embedding_type": "absolute", | |
| "problem_type": "single_label_classification", | |
| "transformers_version": "4.57.1", | |
| "type_vocab_size": 2, | |
| "use_cache": true, | |
| "vocab_size": 28996 | |
| } | |